4D Molecular Therapeutics (NASDAQ:FDMT) Announces Earnings Results, Misses Estimates By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its earnings results on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT opened at $4.53 on Friday. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25. The firm has a market cap of $209.41 million, a PE ratio of -1.59 and a beta of 2.81. The business has a fifty day moving average of $5.22 and a 200-day moving average of $8.59.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $15.00 in a report on Monday, January 13th. Leerink Partners reduced their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. Finally, Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.